{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:13:49Z","timestamp":1792192429310,"version":"4.4.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.leukres.2017.04.006","type":"journal-article","created":{"date-parts":[[2017,4,23]],"date-time":"2017-04-23T14:31:25Z","timestamp":1492957885000},"page":"63-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders\u2013A consensus project of the Italian Society of Hematology"],"prefix":"10.1016","volume":"58","author":[{"given":"Paola","family":"Guglielmelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pietra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pancrazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sante","family":"Tura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Barosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2017.04.006_bib0005","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.04.006_bib0010","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s11899-015-0285-y","article-title":"What do molecular tests. Add to prognostic stratification in MF: is it time to add these to our clinical practice?","volume":"10","author":"Guglielmelli","year":"2015","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2017.04.006_bib0015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/ijlh.12353","article-title":"Molecular genetic evaluation of myeloproliferative neoplasms","volume":"37","author":"Azzato","year":"2015","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.leukres.2017.04.006_bib0020","first-page":"655","article-title":"How to use the nominal group and Delphi techniques","volume":"38","author":"McMillan","year":"2016","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.leukres.2017.04.006_bib0025","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nsmb.2849","article-title":"Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase","volume":"21","author":"Shan","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.leukres.2017.04.006_bib0030","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1182\/blood-2005-06-2600","article-title":"An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor","volume":"107","author":"Staerk","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.04.006_bib0035","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/ajh.23138","article-title":"A novel mutation in MPL (Y252H) results in increased thrombopoietin sensitivity in essential thrombocythemia","volume":"87","author":"Lambert","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2017.04.006_bib0040","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.04.006_bib0045","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.04.006_bib0050","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood-2015-09-671172","article-title":"Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms","volume":"127","author":"Araki","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.04.006_bib0055","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants","volume":"127","author":"Chachoua","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.04.006_bib0060","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","article-title":"Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation","volume":"6","author":"Elf","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.leukres.2017.04.006_bib0065","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1182\/blood-2015-11-679571","article-title":"Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis","volume":"127","author":"Marty","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.04.006_bib0070","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/bjh.12969","article-title":"JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort","volume":"167","author":"McGaffin","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2017.04.006_bib0075","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s12288-016-0658-y","article-title":"Coexisting JAK2V617F and CALR exon 9 mutation in essential thrombocythemia","volume":"32","author":"Rashid","year":"2016","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"10.1016\/j.leukres.2017.04.006_bib0080","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-2141.2009.07671.x","article-title":"Different lineage involvement in myelodysplastic\/myeloproliferative disease with combined MPLW515L and JAK2V617F mutation","volume":"145","author":"Hussein","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2017.04.006_bib0085","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1038\/bcj.2015.21","article-title":"Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis","volume":"5","author":"Lim","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2017.04.006_bib0090","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1038\/leu.2014.148","article-title":"Calreticulin mutations and long-term survival in essential thrombocythemia","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.04.006_bib0095","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.04.006_bib0100","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.04.006_bib0105","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/leu.2013.382","article-title":"Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis","volume":"28","author":"Chi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.04.006_bib0110","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000366263","article-title":"Frequency and molecular characteristics of calreticulin gene (CALR) mutations in patients with JAK2 -negative myeloproliferative neoplasms","volume":"133","author":"Wojtaszewska","year":"2015","journal-title":"Acta Haematol."},{"key":"10.1016\/j.leukres.2017.04.006_bib0115","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s00277-014-2151-8","article-title":"Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia","volume":"93","author":"Chen","year":"2014","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2017.04.006_bib0120","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.04.006_bib0125","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2 CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.04.006_bib0130","doi-asserted-by":"crossref","first-page":"E320","DOI":"10.1002\/ajh.24378","article-title":"The different prognostic impact of type-1 or type-1 like and type-2 or type-2 like CALR mutations in patients with primary myelofibrosis","volume":"91","author":"Li","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2017.04.006_bib0135","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.04.006_bib0140","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","article-title":"Prevalence and. clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.04.006_bib0145","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders","volume":"111","author":"Pietra","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.04.006_bib0150","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMc1006966","article-title":"LNK mutations in JAK2 mutation-negative erythrocytosis","volume":"363","author":"Lasho","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"May","key":"10.1016\/j.leukres.2017.04.006_bib0155","article-title":"Apparent \u2018JAK2-negative' polycythaemia vera due to compound mutations in exon 14","author":"Tiong","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2017.04.006_bib0160","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1038\/sj.leu.2404325","article-title":"Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: d620E and E627E","volume":"20","author":"Schnittger","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.04.006_bib0165","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/sj.leu.2404654","article-title":"JAK2 V617F due to a novel TG \u2212> CT mutation at nucleotides 1848\u20131849: diagnostic implication","volume":"21","author":"Wong","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.04.006_bib0170","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2009-12-257501","article-title":"Failure of the Ipsogen MutaScreen kit to detect the JAK2 617V>F mutation in samples with additional rare exon 14 mutations: implications for clinical testing and report of a novel 618C>F mutation in addition to 617V>F","volume":"115","author":"Warshawsky","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.04.006_bib0175","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/sj.leu.2404419","article-title":"Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera","volume":"20","author":"Gr\u00fcnebach","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.04.006_bib0180","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/leu.2010.23","article-title":"JAK2 mutation and disease phenotype: a double L611V\/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1\/2 rather than STAT5","volume":"24","author":"Cleyrat","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.04.006_bib0185","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2257.2006.00864.x","article-title":"The investigation of JAK2 mutation in Chinese myeloproliferative diseases-identification of a novel C616Y point mutation in a PV patient","volume":"29","author":"Zhang","year":"2007","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.leukres.2017.04.006_bib0190","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cancergencyto.2008.09.010","article-title":"JAK2 V617F\/C618R mutation in a patient with polycythemia vera: a case study and review of the literature","volume":"189","author":"Yoo","year":"2009","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.leukres.2017.04.006_bib0195","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2353\/jmoldx.2009.080114","article-title":"Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias","volume":"11","author":"Ma","year":"2009","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.leukres.2017.04.006_bib0200","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Milosevic Feenstra","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.04.006_bib0205","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","article-title":"Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients","volume":"127","author":"Cabagnols","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.04.006_bib0210","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.04.006_bib0215","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.04.006_bib0220","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.04.006_bib0225","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.leu.2404861","article-title":"Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow","volume":"22","author":"Larsen","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.04.006_bib0230","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/sj.leu.2404588","article-title":"Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F)","volume":"21","author":"Hermouet","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.04.006_bib0235","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.04.006_bib0240","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.leukres.2017.04.006_bib0245","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.04.006_bib0250","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.04.006_bib0255","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3324\/haematol.2009.021444","article-title":"Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia","volume":"95","author":"Antonioli","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2017.04.006_bib0260","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.3324\/haematol.2013.087742","article-title":"JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug","volume":"98","author":"Kuriakose","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2017.04.006_bib0265","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon \u03b1-2a","volume":"122","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.04.006_bib0270","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.04.006_bib0275","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations","volume":"126","author":"Verger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.04.006_bib0280","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","article-title":"The effect of long-term ruxolitinib treatment on JAK2p. V617F allele burden in patients with myelofibrosis","volume":"126","author":"Deininger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.04.006_bib0285","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2015-01-624536","article-title":"JAK2V617F complete molecular remission in polycythemia vera\/essential thrombocythemia patients treated with ruxolitinib","volume":"125","author":"Pieri","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.04.006_bib0290","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A pilot study of the telomerase inhibitor imetelstat for myelofibrosis","volume":"373","author":"Tefferi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.04.006_bib0295","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/leu.2013.219","volume":"27","author":"Jovanovic","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.04.006_bib0300","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/bmt.2009.367","article-title":"Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT","volume":"45","author":"Alchalby","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.leukres.2017.04.006_bib0305","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3324\/haematol.2012.076901","article-title":"JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse","volume":"98","author":"Lange","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2017.04.006_bib0310","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1182\/blood-2008-11-190975","article-title":"JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation","volume":"113","author":"Kr\u00f6ger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.04.006_bib0315","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/bjh.12904","article-title":"Assessment of CALR mutations in myelofibrosis patients, post-allogeneic stem cell transplantation","volume":"166","author":"Haslam","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2017.04.006_bib0320","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3324\/haematol.13486","article-title":"Concordance of assays designed for the quantification of JAK2V617F: a multicenter study","volume":"94","author":"Lippert","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2017.04.006_bib0325","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2353\/jmoldx.2010.090068","article-title":"Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory","volume":"12","author":"Merker","year":"2010","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.leukres.2017.04.006_bib0330","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/leu.2013.219","volume":"27","author":"Schwemmers","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.04.006_bib0335","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.04.006_bib0340","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jmoldx.2013.04.006","article-title":"A multiplexed fragment analysis-based assay for detection of JAK2 exon 12 mutations","volume":"15","author":"Furtado","year":"2013","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.leukres.2017.04.006_bib0345","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jmoldx.2010.12.002","article-title":"Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of JAK2 exon 12 mutations\u2013clinical relevance in the monitoring of polycythemia","volume":"13","author":"Carillo","year":"2011","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.leukres.2017.04.006_bib0350","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.leukres.2014.11.019","article-title":"Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms","volume":"39","author":"Jones","year":"2015","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2017.04.006_bib0355","doi-asserted-by":"crossref","first-page":"52614","DOI":"10.18632\/oncotarget.10376","article-title":"CALR mutation characterization in myeloproliferative neoplasms","volume":"7","author":"Bilbao-Sieyro","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2017.04.006_bib0360","doi-asserted-by":"crossref","DOI":"10.1136\/jclinpath-2016-203940","article-title":"Novel germline mutations in the calreticulin gene: implications for the diagnosis of myeloproliferative neoplasms","author":"Szuber","year":"2016","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.leukres.2017.04.006_bib0365","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00277-014-2232-8","article-title":"Calreticulin mutations in myeloproliferative neoplasms and new methodology for their detection and monitoring","volume":"94","author":"Chi","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2017.04.006_bib0370","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3324\/haematol.2010.034793","article-title":"Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms","volume":"96","author":"Pietra","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2017.04.006_bib0375","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.04.006_bib0380","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1751-553X.2008.01118.x","article-title":"Rapid real-time PCR assay for detection of MPL W515L mutation in patients with chronic myeloproliferative disorders","volume":"32","author":"Ghaderi","year":"2010","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.leukres.2017.04.006_bib0385","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2353\/jmoldx.2008.080015","article-title":"A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction","volume":"10","author":"Pancrazzi","year":"2008","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.leukres.2017.04.006_bib0390","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.leukres.2011.04.012","article-title":"Novel multiplex bead-based assay with LNA-modified probes for detection of MPL exon 10 mutations","volume":"35","author":"Ivanova","year":"2011","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2017.04.006_bib0395","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.cca.2009.10.012","article-title":"Sensitive detection of MPLW515L\/K mutations by amplification refractory mutation system (ARMS)-PCR","volume":"411","author":"Zhuge","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.leukres.2017.04.006_bib0400","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jmoldx.2013.07.006","article-title":"Detection of MPL mutations by a novel allele-specific PCR-based strategy","volume":"15","author":"Furtado","year":"2013","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.leukres.2017.04.006_bib0405","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-2141.2010.08083.x","article-title":"Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis","volume":"149","author":"Boyd","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2017.04.006_bib0410","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3324\/haematol.13224","article-title":"Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis","volume":"94","author":"Schnittger","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2017.04.006_bib0415","doi-asserted-by":"crossref","first-page":"30084","DOI":"10.18632\/oncotarget.8310","article-title":"Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms","volume":"27","author":"Bartels","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2017.04.006_bib0420","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00277-016-2623-0","article-title":"Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR","volume":"95","author":"Waterhouse","year":"2016","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2017.04.006_bib0425","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/ijlh.12404","article-title":"Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms","volume":"37","author":"Fontanelli","year":"2015","journal-title":"Int. J. Lab. Hematol."},{"issue":"July","key":"10.1016\/j.leukres.2017.04.006_bib0430","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s00277-016-2739-2","article-title":"Droplet digital PCR assay for quantifying of CALR mutant allelic burden in myeloproliferative neoplasms","volume":"95","author":"Anelli","year":"2016","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2017.04.006_bib0435","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jmoldx.2010.12.002","article-title":"Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of JAK2 exon 12 mutations\u2013clinical relevance in the monitoring of polycythemia","volume":"13","author":"Carillo","year":"2011","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.leukres.2017.04.006_bib0440","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/bmt.2009.367","article-title":"Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT","volume":"45","author":"Alchalby","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.leukres.2017.04.006_bib0445","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3324\/haematol.13486","article-title":"Concordance of assays designed for the quantification of JAK2V617F: a multicenter study","volume":"94","author":"Lippert","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2017.04.006_bib0450","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1038\/bcj.2012.11","article-title":"Clonal evolution in UKE-1 cell line leading to an increase in JAK2 copy number","volume":"2","author":"Buors","year":"2012","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2017.04.006_bib0455","unstructured":"http:\/\/www.nibsc.org\/products\/brm_product_catalogue_detail_page.aspx?catid=16\/120."},{"key":"10.1016\/j.leukres.2017.04.006_bib0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1098-1004(1998)11:1<1::AID-HUMU1>3.0.CO;2-O","article-title":"Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group","volume":"11","author":"Antonarakis","year":"1998","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.leukres.2017.04.006_bib0465","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.12075","article-title":"Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations","volume":"160","author":"Bench","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2017.04.006_bib0470","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jmoldx.2013.07.002","article-title":"Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology","volume":"15","author":"Gong","year":"2013","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.leukres.2017.04.006_bib0475","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ejh.12578","article-title":"Molecular diagnostics of myeloproliferative neoplasms","volume":"95","author":"Langabeer","year":"2015","journal-title":"Eur. J. Haematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261730111X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261730111X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T18:43:29Z","timestamp":1719168209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261730111X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":95,"alternative-id":["S014521261730111X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2017.04.006","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders\u2013A consensus project of the Italian Society of Hematology","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2017.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}